Future studies will further investigate this topic by evaluating tumor-infiltrating lymphocytes and CXCL14 expression in the tumor microenvironment, especially comparing CDX-2 positive cases with CDX-2 negative cases. The gene discussed is CXCL14; the disease is neoplasm.